Abcam, ab258705, Human STK17A knockout HeLa cell lysate

Size: 1Kit
STK17A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-STK17A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
STK17A also known as DRAK1 is a serine/threonine-protein kinase with a mass of approximately 45 kDa. This protein performs a role in cellular signal transduction by phosphorylating serine and threonine residues on target substrates. STK17A is expressed in a variety of human tissues with significant expression in the brain heart and skeletal muscle indicating its widespread regulatory functions.
Biological function summary
The kinase activity of STK17A affects processes like apoptosis and cell migration. It does not form a complex with other proteins but can directly interact with them to exert its influence. Through these interactions STK17A can regulate cell survival and death which are important in development and homeostasis within an organism.
Pathways
STK17A acts in the apoptosis signaling pathway and is known to modulate JNK (c-Jun N-terminal kinase) signaling. In the apoptosis pathway STK17A can modify the response of cells to stress stimuli effectively controlling programmed cell death. It shows functional association with proteins such as caspases which carry out the execution phase of apoptosis thereby linking STK17A to these essential cellular processes.
Dysregulation of STK17A has connections to cancer and neurodegenerative disorders. In cancer altered STK17A expression or activity can contribute to inappropriate cell survival and proliferation making it a relevant marker or target in tumor biology. It associates with proteins like Bcl-2 which are involved in promoting cell survival. In neurodegenerative disorders such as Alzheimer's disease changes in STK17A expression or function might affect neuronal apoptosis contributing to the pathology of these conditions.